Table of Content

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16

2 Market Overview and Dynamics 18
2.1 Market Size and Forecast 18
2.1.1 Impact of COVID-19 on World Economy 19
2.1.2 Impact of COVID-19 on the Market 21
2.2 Major Growth Drivers 23
2.3 Market Restraints and Challenges 27
2.4 Emerging Opportunities and Market Trends 30
2.5 Porter’s Fiver Forces Analysis 34

3 Segmentation of North America Market by Product Type 38
3.1 Market Overview by Product Type 38
3.2 Active Pharmaceutical Ingredients (API) 40
3.2.1 Branded Drugs 41
3.2.2 Generic Drugs 42
3.3 Finished Dosage Formulations (FDF) 43
3.3.1 Oral Solid Drugs 45
3.3.2 Injectable Drugs 46
3.3.3 Semi-solid or Liquid Drugs 47
3.3.4 Other FDFs 48

4 Segmentation of North America Market by Service Type 49
4.1 Market Overview by Service Type 49
4.2 Preclinical Use 51
4.3 Clinical Use 52
4.3.1 Phase I 54
4.3.2 Phase II 55
4.3.3 Phase III 56
4.3.4 Phase IV 57
4.4 Commercial Use 58

5 Segmentation of North America Market by Customer Type 59
5.1 Market Overview by Customer Type 59
5.2 Pharmaceutical Firms 61
5.3 Biotechnology Firms 62

6 Segmentation of North America Market by Therapeutic Area 63
6.1 Market Overview by Therapeutic Area 63
6.2 Infectious Diseases 65
6.3 Oncology 66
6.4 Ophthalmology 67
6.5 Cardiovascular Disorders 68
6.6 Central Nervous System 69
6.7 Respiratory Disorders 70
6.8 Metabolic Diseases 71
6.9 Other Therapeutic Areas 72

7 North America Market 2021-2031 by Country 73
7.1 Overview of North America Market 73
7.2 U.S. 76
7.3 Canada 79
7.4 Mexico 81

8 Competitive Landscape 83
8.1 Overview of Key Vendors 83
8.2 New Product Launch, Partnership, Investment, and M&A 86
8.3 Company Profiles 87
Boehringer Ingelheim 87
Cambrex Corporation 89
Catalent 90
Cipla 91
Covance Inc. 92
Lonza Group Ltd. 93
Medley Pharmaceuticals 94
NatcoPharma 95
Patheon (Thermo Fisher Scientific, Inc.) 96
Piramal Pharma Solutions 97
RedHillBiopharma 98
Siegfried Holding AG 99
STA Pharmaceutical 100
Sun Pharmaceutical 101
Teva 102
RELATED REPORTS 103



List of Figures

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Small Molecule CDMO Market, 2021-2031, $ mn 18
Figure 5. Impact of COVID-19 on Business 21
Figure 6. Primary Drivers and Impact Factors of North America Small Molecule CDMO Market 23
Figure 7. Primary Restraints and Impact Factors of North America Small Molecule CDMO Market 27
Figure 8. Investment Opportunity Analysis 31
Figure 9. Porter’s Fiver Forces Analysis of North America Small Molecule CDMO Market 34
Figure 10. Breakdown of North America Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 39
Figure 11. North America Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 39
Figure 12. North America Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 40
Figure 13. North America Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 41
Figure 14. North America Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 42
Figure 15. North America Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 43
Figure 16. North America Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 45
Figure 17. North America Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 46
Figure 18. North America Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 47
Figure 19. North America Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 48
Figure 20. Breakdown of North America Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 50
Figure 21. North America Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 50
Figure 22. North America Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 51
Figure 23. North America Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 52
Figure 24. North America Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 54
Figure 25. North America Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 55
Figure 26. North America Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 56
Figure 27. North America Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 57
Figure 28. North America Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 58
Figure 29. Breakdown of North America Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 60
Figure 30. North America Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 60
Figure 31. North America Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 61
Figure 32. North America Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 62
Figure 33. Breakdown of North America Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 64
Figure 34. North America Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 64
Figure 35. North America Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 65
Figure 36. North America Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 66
Figure 37. North America Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 67
Figure 38. North America Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 68
Figure 39. North America Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 69
Figure 40. North America Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 70
Figure 41. North America Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 71
Figure 42. North America Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 72
Figure 43. Breakdown of North America Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 74
Figure 44. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 75
Figure 45. U.S. Small Molecule CDMO Market, 2021-2031, $ mn 77
Figure 46. Canada Small Molecule CDMO Market, 2021-2031, $ mn 79
Figure 47. Small Molecule CDMO Market in Mexico, 2021-2031, $ mn 81
Figure 48. Growth Stage of North America Small Molecule CDMO Industry over the Forecast Period 83

List of Tables

List of Tables:

Table 1. Snapshot of North America Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 20
Table 3. Worldwide Total Number of Registered Clinical Trials 26
Table 4. Main Product Trends and Market Opportunities in North America Small Molecule CDMO Market 30
Table 5. North America Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 38
Table 6. North America Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 40
Table 7. North America Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 44
Table 8. North America Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 49
Table 9. North America Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 53
Table 10. North America Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 59
Table 11. North America Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 63
Table 12. North America Small Molecule CDMO Market by Country, 2021-2031, $ mn 74
Table 13. U.S. Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 78
Table 14. U.S. Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 78
Table 15. U.S. Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 78
Table 16. Canada Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 80
Table 17. Canada Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 80
Table 18. Canada Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 80
Table 19. Mexico Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 82
Table 20. Mexico Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 82
Table 21. Mexico Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 82
Table 22. Boehringer Ingelheim: Company Snapshot 87
Table 23. Boehringer Ingelheim: Business Segmentation 88
Table 24. Boehringer Ingelheim: Product Portfolio 88